Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q ... professional commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion ... by too quickly to process with the naked eye. , Slow motion ...
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , the leader in products ... Spirax Sarco Anytime. This platform, offering unique online ordering capabilities, is only available ... Log on to Spirax Sarco Anytime and within minutes you can be making ...
(Date:9/1/2015)... , Sept. 1, 2015 Prostate ... death in American men. One in seven ... 233,000 new cases are diagnosed annually. That said, ... using a powerful new technique, MRI Fusion Biopsy, ... large cancer lesions, treating only the affected areas ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... announced today that the National Institutes of Health (NIH) has awarded the company ... administered by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. ...
Breaking Biology Technology:Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3
... on target drug delivery. , ... Cary, NC (PRWEB) ... Inc. company ) and Auburn University announced today a joint research ... of Veterinary Medicine,s Department of Pathobiology, the six-month study is under ...
... State will receive $5 million over four years ... National Center for Nanotechnology Applications and Career Knowledge ... leader in nanotechnology education and workforce development since ... home to the NSF Regional Center for Nanofabrication ...
... Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE, TROFILE(TM) ... ... SOUTH SAN FRANCISCO, Calif., Oct. 23 Monogram,Biosciences, Inc., ... conference,call on Monday, October 27, 2008 at 4:30 p.m. (Eastern ...
Cached Biology Technology:Calvert Research and Auburn University Announce Joint Venture 2Calvert Research and Auburn University Announce Joint Venture 3Penn State gets $5M NSF grant for Nanotech Applications and Career Knowledge 2Monogram Announces Conference Call 2
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... NEW YORK , Aug. 12, 2015 /PRNewswire/ ... how hackers can attack Android phones to steal ... identifies the increasing availability of fingerprint scanners on ... of utmost concern. To secure biometrics on mobile ... platform to augment these convenient authentication systems with ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2
... more than three times as many mutations from their fathers ... father,s age but not the mother,s, researchers have found in ... The study, based on the DNA of around 85,000 Icelanders, ... providing estimates of when human ancestors diverged from nonhuman primates. ...
... have many functions in the central nervous system, such ... the brain,s response to neurotrauma or stroke. ... with collaborators have earlier demonstrated that astrocytes reduce the ... of transplanted neural stem cells can be largely improved ...
... (August 23, 2012) University of Minnesota Medical School ... from Genentech, Inc., to discover how some proteins may ... The proteins part of R-spondin family normally ... of Minnesota researchers have discovered that when two types ...
Cached Biology News:Most mutations come from dad 2Most mutations come from dad 3Astrocytes control the generation of new neurons from neural stem cells 2U of M researchers: Newly discovered genetic markers could signal colon cancer development 2
Request Info...
... TURBO DNase (patent pending) was developed using ... changes into the DNA binding pocket of wild-type ... of the protein for DNA. The result is ... Km for DNA, and an ability to maintain ...
Request Info...
Request Info...
Biology Products: